Literature DB >> 2002020

Demonstration of peptidoglycan-binding sites on lymphocytes and macrophages by photoaffinity cross-linking.

R Dziarski1.   

Abstract

One dominant binding site (70 kDa 6.5 pI protein) for bacterial cell wall peptidoglycan (PGN), a macrophage activator and polyclonal B cell mitogen, was demonstrated on mouse B and T lymphocytes and macrophages by photoaffinity cross-linking and two-dimensional polyacrylamide gel electrophoresis. This binding site was not present on erythrocytes. The binding was specific for polymeric PGN and was competitively inhibited by unlabeled PGN with IC50 = 48 micrograms/ml (0.38 microM). The binding was partially inhibited by O-acetylated PGN monomers (IC50 = 469 micrograms/ml, 521 microM), dextran sulfate (IC50 = 1024 micrograms/ml, 124 microM), and (GlcNAc)3 (IC50 = 6.6 mg/ml, 10 mM), and was not inhibited by non-O-acetylated PGN monomers and dimers, muramyl dipeptide, PGN pentapeptide, GlcNAc, teichoic acid, protein A, and gelatin. The cell surface location of the 70-kDa PGN-binding protein was indicated by the ability of PGN to bind to this protein in intact metabolically inactive cells (at 4 degrees C and in the presence of 0.1% NaN3) and by the ability to extract the 70-kDa PGN-binding protein from viable B lymphocytes by noncytotoxic concentration of n-octyl-beta-D-glucopyranoside.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2002020

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

Review 1.  Endogenous synthesis of peptidoglycan in eukaryotic cells; a novel concept involving its essential role in cell division, tumor formation and the biological clock.

Authors:  C A Roten; D Karamata
Journal:  Experientia       Date:  1992-10-15

2.  Specific binding of soluble peptidoglycan and muramyldipeptide to CD14 on human monocytes.

Authors:  B Weidemann; J Schletter; R Dziarski; S Kusumoto; F Stelter; E T Rietschel; H D Flad; A J Ulmer
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

Review 3.  Bacterial modulins: a novel class of virulence factors which cause host tissue pathology by inducing cytokine synthesis.

Authors:  B Henderson; S Poole; M Wilson
Journal:  Microbiol Rev       Date:  1996-06

4.  Staphylococcus aureus peptidoglycan is a toll-like receptor 2 activator: a reevaluation.

Authors:  Roman Dziarski; Dipika Gupta
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

5.  Anti-CD14 monoclonal antibodies inhibit the production of tumor necrosis factor alpha and interleukin-10 by human monocytes stimulated with killed and live Haemophilus influenzae or Streptococcus pneumoniae organisms.

Authors:  A M van Furth; E M Verhard-Seijmonsbergen; J A Langermans; J T van Dissel; R van Furth
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

6.  Lipopolysaccharide (LPS) recognition in macrophages. Participation of LPS-binding protein and CD14 in LPS-induced adaptation in rabbit peritoneal exudate macrophages.

Authors:  J Mathison; E Wolfson; S Steinemann; P Tobias; R Ulevitch
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

Review 7.  Modulins: a new class of cytokine-inducing, pro-inflammatory bacterial virulence factor.

Authors:  B Henderson; M Wilson
Journal:  Inflamm Res       Date:  1995-05       Impact factor: 4.575

8.  The 70-kilodalton pertussis toxin-binding protein in Jurkat cells.

Authors:  G D Armstrong; C G Clark; L D Heerze
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

9.  A lipooligosaccharide-binding site on HepG2 cells similar to the gonococcal opacity-associated surface protein Opa.

Authors:  N Porat; M A Apicella; M S Blake
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

10.  Soluble peptidoglycan-induced monokine production can be blocked by anti-CD14 monoclonal antibodies and by lipid A partial structures.

Authors:  B Weidemann; H Brade; E T Rietschel; R Dziarski; V Bazil; S Kusumoto; H D Flad; A J Ulmer
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.